Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.5K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.5K
Rh Blood Group01:19

Rh Blood Group

2.0K
The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.
2.0K
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

1.6K
Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
1.6K
Transmission-based Precautions I: Contact, Enteric, and Droplets01:17

Transmission-based Precautions I: Contact, Enteric, and Droplets

4.2K
Transmission-based precautions are for patients known to be infected or suspected to be infected or colonized with organisms that pose a significant risk to others. Some transmission-based precautions include contact, enteric, and droplet.
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...
4.2K
Relative Risk01:12

Relative Risk

476
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
476
Standard Precaution01:26

Standard Precaution

2.3K
Standard precautions are the minimum infection control safeguards used while caring for all patients, irrespective of their disease condition. They help prevent the spread of common infectious microorganisms to healthcare workers, patients, and visitors in all healthcare settings.
Hand hygiene is the most crucial means to prevent the transmission of disease. Employers are legally required to provide their workers with personal protective equipment (PPE) to minimize exposure or contact with...
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Whole genome sequencing of measles viruses: the benefit for outbreak investigation, The Netherlands, 2013-2014.

Virus genes·2026
Same author

Innate airway responses shape permissiveness to human respiratory syncytial virus.

Virus research·2026
Same author

Subacute Sclerosing Panencephalitis: How Measles Virus Adapts to the Brain.

Annual review of virology·2026
Same author

Broad-spectrum antiviral screening reveals pyrimidine biosynthesis as a target for inhibiting measles virus replication.

Antiviral research·2026
Same author

Structural and mechanistic basis for antibody neutralization of the measles fusion protein.

Nature communications·2026
Same author

Applications and limitations of respiratory virus infection models in well-differentiated airway epithelial cell cultures of livestock.

Current opinion in virology·2025

Related Experiment Video

Updated: Oct 6, 2025

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

16.3K

Location matters in RSV protection.

Rik L de Swart1

  • 1Department of Virology, Wageningen Bioveterinary Research, Lelystad, the Netherlands; Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands.

Cell Host & Microbe
|January 13, 2022
PubMed
Summary

Respiratory syncytial virus (RSV) vaccines showed varied protection in primates. Distinct antibody profiles were linked to protection, with specific antibody responses identified as key correlates.

Area of Science:

  • Immunology
  • Virology
  • Vaccinology

Background:

  • Respiratory syncytial virus (RSV) is a major cause of respiratory illness in infants and the elderly.
  • Developing an effective RSV vaccine remains a significant public health challenge.
  • Previous vaccine candidates have shown variable efficacy and safety profiles.

Purpose of the Study:

  • To evaluate the immunogenicity and protective efficacy of six candidate RSV vaccines in non-human primates.
  • To identify antibody correlates of protection associated with different vaccine candidates.
  • To understand the role of antibody profiles in mediating protection against RSV challenge.

Main Methods:

  • Non-human primates were immunized with six distinct RSV vaccine candidates.
  • Systems serology was employed to analyze comprehensive antibody profiles.

More Related Videos

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

11.1K
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

8.0K

Related Experiment Videos

Last Updated: Oct 6, 2025

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

16.3K
An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

11.1K
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

8.0K
  • Protection was assessed following experimental RSV challenge.

    • Main Results:

    • Immunization elicited distinct antibody profiles across the vaccine groups.
    • Variable levels of protection against RSV challenge were observed.
    • Compartment-specific antibody responses were identified as correlates of protection.

    Conclusions:

    • Candidate RSV vaccines induce diverse immune responses.
    • Antibody profiles are critical determinants of vaccine-induced protection.
    • Systems serology can identify key antibody-mediated correlates for vaccine development.